Nkarta (NASDAQ:NKTX) Reaches New 52-Week High After Analyst Upgrade

Nkarta, Inc. (NASDAQ:NKTXGet Free Report)’s stock price reached a new 52-week high during mid-day trading on Wednesday after Mizuho raised their price target on the stock from $9.00 to $31.00. Mizuho currently has a buy rating on the stock. Nkarta traded as high as $14.28 and last traded at $14.21, with a volume of 122638 shares traded. The stock had previously closed at $13.22.

A number of other research analysts have also issued reports on NKTX. Needham & Company LLC restated a “buy” rating and issued a $15.00 target price on shares of Nkarta in a report on Tuesday, December 12th. HC Wainwright upped their price objective on shares of Nkarta from $10.00 to $22.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th.

Get Our Latest Report on NKTX

Insider Activity

In other news, insider David Shook sold 3,552 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $8.74, for a total transaction of $31,044.48. Following the completion of the transaction, the insider now owns 114,980 shares of the company’s stock, valued at approximately $1,004,925.20. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, insider David Shook sold 3,552 shares of the stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $8.74, for a total transaction of $31,044.48. Following the completion of the sale, the insider now owns 114,980 shares of the company’s stock, valued at approximately $1,004,925.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider James Trager sold 4,143 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $12.00, for a total transaction of $49,716.00. Following the sale, the insider now directly owns 149,415 shares of the company’s stock, valued at approximately $1,792,980. The disclosure for this sale can be found here. Insiders sold a total of 17,392 shares of company stock valued at $165,512 in the last 90 days. 5.60% of the stock is currently owned by insiders.

Institutional Trading of Nkarta

Several large investors have recently bought and sold shares of NKTX. Federated Hermes Inc. grew its position in Nkarta by 735.3% in the first quarter. Federated Hermes Inc. now owns 4,711 shares of the company’s stock valued at $54,000 after acquiring an additional 4,147 shares in the last quarter. Wasatch Advisors Inc. grew its position in Nkarta by 33.4% in the first quarter. Wasatch Advisors Inc. now owns 842,302 shares of the company’s stock valued at $9,585,000 after acquiring an additional 210,700 shares in the last quarter. Renaissance Technologies LLC grew its position in Nkarta by 69.7% in the first quarter. Renaissance Technologies LLC now owns 234,000 shares of the company’s stock valued at $2,663,000 after acquiring an additional 96,100 shares in the last quarter. State Street Corp boosted its stake in shares of Nkarta by 1.0% during the 1st quarter. State Street Corp now owns 276,318 shares of the company’s stock valued at $3,144,000 after buying an additional 2,806 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Nkarta by 5.9% during the 1st quarter. Wellington Management Group LLP now owns 27,879 shares of the company’s stock valued at $317,000 after buying an additional 1,554 shares during the last quarter. Institutional investors and hedge funds own 80.54% of the company’s stock.

Nkarta Stock Performance

The company has a market capitalization of $730.19 million, a PE ratio of -5.95 and a beta of 0.73. The company has a 50 day moving average price of $9.77 and a 200 day moving average price of $4.88.

About Nkarta

(Get Free Report)

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells.

Recommended Stories

Receive News & Ratings for Nkarta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nkarta and related companies with MarketBeat.com's FREE daily email newsletter.